Perhexiline is a unique anti-anginal agent that is frequently used in the treatment of chronic
refractory angina. Its utility has been limited because of its complex pharmacokinetics that …

Perhexiline is a drug that is used for treatment of moderate to severe angina pectoris that
has not responded to other treatment. It has a low therapeutic index, and saturable …

Aims 1) To develop an estimate of oral clearance (/F) for the antianginal agent perhexiline
based on the ratio of cis‐OH‐perhexiline metabolite/parent perhexiline plasma …

Aim To define inter‐and intraday variability in plasma perhexiline concentrations, time‐to‐
maximum plasma perhexiline concentration and variability in the ratio of hydroxyperhexiline …

Approaches to the pharmacotherapy of angina pectoris have previously centred on the
concept that a transient imbalance between myocardial oxygen “demand” and supply within …

Perhexiline is a prophylactic antianginal agent developed in the 1970s. Although,
therapeutically, it remained a success, the concerns of its severe adverse effects including …

Perhexiline was introduced about 30 years ago and rapidly gained a reputation for efficacy
in the management of angina pectoris. However, hepatic and neurological adverse effects …

Perhexiline maleate, which causes inhibition of myocardial fatty acid catabolism with a
concomitant increase in glucose utilization, is particularly useful in the management of …

Perhexiline maleate (Pexid®) which has been in general use in France with good results for
the treatment of angina pectoris since 1973, may be associated with severe side effects …

Background: Perhexiline, originally used as a first-line prophylactic antianginal agent, is now
regarded primarily as a treatment for otherwise refractory myocardial ischemia. Recent …